The Impact of Narrow Band Imaging in the Detection and Resection of Bladder Tumor in Transitional Cell Carcinoma of the Bladder: A Prospective, Blinded, Sequential Intervention Randomized Controlled Trial

Mukherjee, Partho; George, Arun Jacob Philip; Yadav, Bijesh; Jeyaseelan, Lakshmanan; Kumar, Rajesh; Mukha, Rajiv Paul; Chandrasingh, J; Kumar, Santosh; Kekre, Nitin S; Devasia, Antony

doi:10.1016/j.urology.2019.01.039

Cited by 13 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The real advantage of NBI, however, remains to be proven, since published data are limited and not in agreement. Mukherjee et al showed in a randomized controlled trial NBI to be better in tumor detection and resection as compared to white light [ 16 ], whereas an earlier and larger study did not show a difference in recurrence rate after 1 year of follow-up [ 17 ].…”

Section: Enhanced Cystoscopy and Imaging For Follow-upmentioning

confidence: 99%

Follow-up in non-muscle invasive bladder cancer: facts and future

Witjes¹

2020

World J Urol

View full text Add to dashboard Cite

Patients with non-muscle invasive bladder cancer (NMIBC) have high recurrence and progression rates in spite of tumor resection and adjuvant instillation therapy. To detect recurrences and progression, these patients remain under frequent follow-up. Follow-up, however, is not well defined. Frequency and duration of follow recommendations are based on low levels of evidence, which is illustrated by clear differences in these recommendations per guideline, even when specified per risk group. Additionally, follow-up is recommended with cystoscopy and cytology in selected patients, which both have clear limitations. Fact is that follow-up in NMIBC is too frequent, with low levels of evidence and suboptimal tools, and it is patient unfriendly and costly. Improved cystoscopy techniques are unproven or impractical in the outpatient follow-up setting. Urinary markers have been around for decades, but never widely used in clinical practice. New (epi)genetic markers, however, could play a significant role in future follow-up of NMIBC. They have been shown to have very high negative predictive values for recurrences in follow-up of NMIBC, especially high-grade recurrences. Several studies suggested that these markers could be used to adapt follow-up cystoscopy frequency. What still needs study and confirmation is the cost-effectiveness of the use of these markers, which is highly dependent on health care costs per country and marker price. In all, however, implementation of these new urinary markers after confirmation of current results might significantly reduce patient burden and health care costs in the near future without reducing quality.

show abstract

Section: Enhanced Cystoscopy and Imaging For Follow-upmentioning

confidence: 99%

Follow-up in non-muscle invasive bladder cancer: facts and future

Witjes¹

2020

World J Urol

View full text Add to dashboard Cite

show abstract

“…Bladder tumors are better visualized due to their increased vascularity, appearing as dark brown or green against a normal mucosal white or pink background [49]. NBI detects 9-56% more tumors compared to WLC [50]. A meta-analysis of randomized control trials showed no difference in recurrence rates between NBI and HAL-based BLC, lower recurrence with 5-ALA based BLC compared to NBI and HAL-based BLC, and lower recurrence of any 5-ALA and HAL-based BLC and NBI compared to WLC [51].…”

Section: Managementmentioning

confidence: 99%

Imaging and Management of Bladder Cancer

Wong

Ganeshan

Jensen

et al. 2021

Cancers

View full text Add to dashboard Cite

Methods: Keyword searches of Medline, PubMed, and the Cochrane Library for manuscripts published in English, and searches of references cited in selected articles to identify additional relevant papers. Abstracts sponsored by various societies including the American Urological Association (AUA), European Association of Urology (EAU), and European Society for Medical Oncology (ESMO) were also searched. Background: Bladder cancer is the sixth most common cancer in the United States, and one of the most expensive in terms of cancer care. The overwhelming majority are urothelial carcinomas, more often non-muscle invasive rather than muscle-invasive. Bladder cancer is usually diagnosed after work up for hematuria. While the workup for gross hematuria remains CT urography and cystoscopy, the workup for microscopic hematuria was recently updated in 2020 by the American Urologic Association with a more risk-based approach. Bladder cancer is confirmed and staged by transurethral resection of bladder tumor. One of the main goals in staging is determining the presence or absence of muscle invasion by tumor which has wide implications in regards to management and prognosis. CT urography is the main imaging technique in the workup of bladder cancer. There is growing interest in advanced imaging techniques such as multiparametric MRI for local staging, as well as standardized imaging and reporting system with the recently created Vesicle Imaging Reporting and Data System (VI-RADS). Therapies for bladder cancer are rapidly evolving with immune checkpoint inhibitors, particularly programmed death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) inhibitors, as well as another class of immunotherapy called an antibody-drug conjugate which consists of a cytotoxic drug conjugated to monoclonal antibodies against a specific target. Conclusion: Bladder cancer is a complex disease, and its management is evolving. Advances in therapy, understanding of the disease, and advanced imaging have ushered in a period of rapid change in the care of bladder cancer patients.

show abstract

“…However, interpretation of images is inherently subjective and relies on individual ability to detect visual change in the vasculature around the suspicious areas. Therefore, bleeding during TURBT could significantly reduce enhanced visualization and subsequently, NBI's accuracy in detecting additional lesions or assessing adequate resection (11,12). Additionally, there is lack of consistent evidence suggesting an improved tumor recurrence or progression by use of NBI.…”

Section: Nbimentioning

confidence: 99%